Evaluation of 6-11C-methyl-m-tyrosine as a PET probe for presynaptic dopaminergic activity: A comparison PET study with b-11C-L-DOPA and 18F-FDOPA in Parkinson disease monkeys

Journal of Nuclear Medicine

Volumn 57, Issue 2, 2016, Pages 303-308

  Kanazawa, Masakatsu ^a   Ohba, Hiroyuki ^a   Harada, Norihiro ^a   Kakiuchi, Takeharu ^a   Muramatsu, Shin Ichi ^b   Tsukada, Hideo ^a  

^a CENTRAL RESEARCH LABORATORY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

6 11C methyl mtyrosine; 18F FDOPA; ? 11C L DOPA; Dopamine; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6 FLUORODOPA F 18; 6 METHYL 3 TYROSINE C 11; BETA LEVODOPA C 11; CARBIDOPA; DOPAMINE; DOPAMINE TRANSPORTER; TRACER; UNCLASSIFIED DRUG; DOPA; ENZYME INHIBITOR; LEVODOPA; O-(11C)METHYL-L-TYROSINE; PRESYNAPTIC RECEPTOR; RADIOPHARMACEUTICAL AGENT; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; DRUG CLEARANCE; DRUG COMPETITION; DRUG METABOLISM; DRUG UPTAKE; MACACA FASCICULARIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; DOPAMINERGIC NERVE CELL; INTOXICATION; METABOLISM; PROCEDURES; SCINTISCANNING;

ANIMALS; BRAIN; CARBIDOPA; DIHYDROXYPHENYLALANINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; ENZYME INHIBITORS; LEVODOPA; MACACA FASCICULARIS; MPTP POISONING; PARKINSON DISEASE, SECONDARY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, PRESYNAPTIC; TYROSINE;

EID: 84958658803     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.161802     Document Type: Article

References (38)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet. 2009;373:2055-2066.
2. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 1990;54: 823-827.
3. Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol. 1996;40:663-671.
4. Brooks DJ. Imaging approaches to Parkinson disease. J Nucl Med. 2010;51:596-609.
5. 11C-labelled L-tyrosine and L-DOPA. Acta Chem Scand. 1990;44:183-188.
6. 11C]DOPA disposition in the monkey brain. Brain Res. 1996;713:92-98.
7. 18F]fluoro-Ldopa and [3H]L-dopa in rats. Biochem Pharmacol. 1990;39:1853-1860.
8. Tsukada H, Harada N, Nishiyama S, Ohba H, Kakiuchi T. Cholinergic neuronal modulation alters dopamine D2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: PET studies with microdialysis in the conscious monkey brain. J Neurosci. 2000;20:7067-7073.
9. 11C] raclopride binDing with no alteration in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multi-parametric PET studies combined with microdialysis analysis. Synapse. 2000;37:95-103.
10. Muramatsu S, Okuno T, Suzuki Y, et al. Multitracer assessment of dopamine function after transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson's disease. Synapse. 2009;63:541-548.
11. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacts of the substantia nigra by MPTP. Proc Natl Acad Sci U S A. 1983;80:4546-4550.
12. Kuwabara H, Cumming P, Yasuhara Y, et al. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. J Nucl Med. 1995;36:1226-1231.
13. 18F-fluorodopa data. J Cereb Blood Flow Metab. 2002;22: 232-239.
14. 18F]fluorodopamine storage capacity. J Cereb Blood Flow Metab. 2005;25:807-819.
15. 18F]fluoro-Ldopa in rat. J Cereb Blood Flow Metab. 1990;10:707-719.
16. 18F]fluoro-l-DOPA in the rhesus monkey brain. J Cereb Blood Flow Metab. 1991;11:726-734.
17. 18F]fluoro-L-dopa and its metabolism in vivo: a critical review. Int J Rad Appl Instrum B. 1992;19:149-158.
18. Lemaire C, Damhaut P, Plenevaux A, Comar D. Enantioselective synthesis of 6-[fluorine-18]-fluoro-L-dopa from no-carrier-added fluorine-18-fluoride. J Nucl Med. 1994;35:1996-2002.
19. 18F]fluoro-L-dopa by chiral phasetransfer alkylation. Eur J Org Chem. 2004;2004:2899-2904.
20. 18F]fluoro-L-m-tyrosine: metabolism, PET kinetics, and MPTP lesions in primates. Brain Res. 1997;750:264-276.
21. DeJesus OT. Positron-labeled DOPA analogs to image dopamine terminals. Drug Dev Res. 2003;59:249-260.
22. 18F]fluoro-L-mtyrosine studies of dopaminergic function in human and nonhuman primates. Front Hum Neurosci. 2007;1:9.
23. Boulton AA, Juorio AV. Cerebral decarboxylation of meta and para-tyrosine. Experientia. 1983;39:130-134.
24. 18F]fluoro-L-m-tyrosine administration. Eur J Nucl Med. 1999;26:1407-1412.
25. 11C-6MemTyr) for dopamine synthesis imaging in living brain using PET. Bioorg Med Chem. 2015;23:729-734.
26. 11C]WIN 35,428). J Labelled Comp Radiopharm. 2006;33:147-152.
27. Watanabe M, Okada H, Shimizu K, et al. A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans Nucl Sci. 1997;44: 1277-1282.
28. Jones EG, Stone JM, Karten HJ. High-resolution digital brain atlases: a Hubble telescope for the brain. Ann N Y Acad Sci. 2011;1225(suppl1):E147-E159.
29. Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res. 1982;257:237-274.
30. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab. 1985;5:584-590.
31. Gjedde A, Reith J, Dyve S, et al. Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci USA. 1991;88:2721-2725.
32. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binDing radioligands. J Cereb Blood Flow Metab. 2007;27: 1533-1539.
33. Barrio JR, Huang S-H, Yu D-C, et al. Radiofluorinated L-m-tyrosines: new invivo probes for central dopamine biochemistry. J Cereb Blood Flow Metab. 1996;16:667-678.
34. 11C]DOPA turnover in the rat striatum with infusion of L-tyrosine. J Neural Transm Gen Sect. 1994;95:1-15.
35. 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system. J Cereb Blood Flow Metab. 1999;19: 1142-1149.
36. 11C]DOPA and its metabolites for the validation of positron emission tomography studies. J Pharm Biomed Anal. 1995;13: 361-367.
37. 18F]6-fluoro-L-3,4-dihydroxy-phenylalanine in the hooded rat. J Neurochem. 1987;48:601-608.
38. Pavese N, Brooks DJ. Imaging neurodegeneration in Parkinson's disease, Biochim Biophys Acta. 2009;1792:722-729.